269.55 0.00 (0.00%)
After hours: 6:44PM EDT
|Bid||261.00 x 800|
|Ask||274.70 x 900|
|Day's Range||260.66 - 270.46|
|52 Week Range||202.83 - 282.98|
|Beta (3Y Monthly)||1.30|
|PE Ratio (TTM)||37.23|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||0.76 (0.28%)|
|1y Target Est||290.73|
Zacks.com featured expert Kevin Matras highlights: Foot Locker, Thermo Fisher Scientific, SS&C Technologies, Columbia Sportswear and Comcast
Boston Scientific stock slipped Wednesday after its first-quarter sales and earnings lagged expectations. But fellow medical technology company Thermo Fisher topped estimates in its report.
While there are several dividend stocks that could provide capital appreciation, honing in on stocks with a history of dividend growth leads to a healthy portfolio with a greater scope of capital appreciation.
(Reuters) - Thermo Fisher Scientific Inc on Wednesday raised its 2019 forecasts for adjusted profit and revenue on the back of its $1.7 billion (£1.3 billion) deal to buy Brammer Bio, and beat the average ...
The Waltham, Massachusetts-based company said it had net income of $2.02 per share. Earnings, adjusted for one-time gains and costs, came to $2.81 per share. The results surpassed Wall Street expectations. ...
Thermo Fisher Scientific Inc on Wednesday raised its 2019 forecasts for adjusted profit and revenue on the back of its $1.7 billion deal to buy Brammer Bio, and beat the average analyst estimate for first-quarter ...
WALTHAM, Mass. , April 24, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 30, ...
Investing.com - Thermo Fisher Scientific (NYSE:TMO) reported first quarter earnings that Beat analysts' expectations on Wednesday and revenue that topped forecasts.
The roll-out of Tandem Diabetes' (TNDM) unique insulin pump platform viz. t:slim X2 with Basal-IQ technology is expected to drive the top line in first-quarter 2019.
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Strong analytical instruments business, product portfolio expansion and prudent growth strategy are likely to support Thermo Fisher (TMO) in Q1. However, forex might act as a dampener.
We are optimistic about Boston Scientific's (BSX) IC business that will help maintain its impressive global growth trend in Q1 owing to an innovative portfolio and strong commercial teams.
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite ongoing customers' transition from HiSeq consumables to NovaSeq, Illumina's (ILMN) Q1 results are expected to gain from this high throughput suite.
Abbott (ABT) expects high single-digit growth in Medical Devices' sales in first-quarter 2019 and continued double-digit growth in certain sub-segments.
Since Thermo Fisher Scientific Inc. (NYSE:TMO) released its earnings in December 2018, analysts seem cautiously optimistic, with profits predicted to increase by 18% next year...